Skip to main content
T&R Biofab Co., Ltd logo

T&R Biofab Co., Ltd — Investor Relations & Filings

Ticker · 246710 ISIN · KR7246710008 KO Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2025-09-08 Capital/Financing Update
Country KR South Korea
Listing KO 246710

About T&R Biofab Co., Ltd

http://www.tnrbiofab.com/en/

T&R Biofab Co., Ltd. is a biomedical engineering company specializing in the development and commercialization of regenerative medical technologies. The company utilizes its proprietary 3D bioprinting technology to manufacture a range of products. Its primary offerings include 3D-printed, bioresorbable medical scaffolds designed to aid in the regeneration and reconstruction of tissues and organs. Other key business areas encompass bio-surgical solutions, the development of organoids and mini-tissues for research and therapeutic applications, and the use of human induced pluripotent stem cells (hiPSC).

Recent filings

Filing Released Lang Actions
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 100% confidence The document is a '증권신고서(지분증권) 정정신고서' (Securities Registration Statement Amendment) filed with the Financial Services Commission (금융위원회) in South Korea. It details the adjustment of the issuance price (1차 발행가액 확정) for a capital increase (유상증자) by T&R Biofab. This is a formal regulatory filing related to capital structure changes and financing, which falls under the 'Capital/Financing Update' category.
2025-09-08 Korean
투자설명서
Investor Presentation Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) issued by T&R Biofab on September 8, 2025. It details a securities offering (capital increase), including the number of shares, offering price, subscription period, and comprehensive risk factors (business, financial, and legal risks). This document is a formal regulatory filing required for public offerings of securities, which falls under the category of Proxy Solicitation & Information Statement (PSI) or, more broadly, a regulatory filing document used for capital raising. Given the specific definitions provided, 'PSI' is the most accurate classification for a formal investment prospectus used to solicit investor participation in a capital raise.
2025-09-08 Korean
권리락 (유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement regarding a 'rights offering' (유상증자) and the resulting 'ex-rights' (권리락) date for T&R Biofab. It provides specific details on the stock code, reference price, and the reason for the capital change. Since it announces a change in capital structure/share issuance rather than a full report or a buyback, it falls under the Share Issue/Capital Change category.
2025-09-08 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the changes in share ownership by KB Asset Management in the company TNR Biofab. This document type is specifically used to notify the market and regulators of significant changes in shareholding levels, which aligns with the 'Major Shareholding Notification' category.
2025-09-02 Korean
[기재정정]증권신고서(지분증권) (2025.10)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by TNR Biofab. It details corrections made to a previously submitted registration statement, specifically updating financial data to reflect the recently submitted 2025 semi-annual report (반기보고서). Since this is a regulatory filing related to a securities offering and does not fit into the specific categories like 10-K, IR, or ER, it is classified as a Regulatory Filing.
2025-08-22 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '티앤알바이오팹' covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business descriptions, capital structure, and management discussions, which are characteristic of an interim financial report. It is not a mere announcement or certification, but the full report itself. H1 2025
2025-08-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.